U.S. Physical Therapy, Inc. (NYSE:USPH) Director Clayton Trier sold 4,250 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $71.97, for a total transaction of $305,872.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

U.S. Physical Therapy, Inc. (NYSE USPH) opened at $72.45 on Wednesday. U.S. Physical Therapy, Inc. has a fifty-two week low of $56.50 and a fifty-two week high of $78.00. The company has a current ratio of 2.04, a quick ratio of 2.04 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $893.89, a price-to-earnings ratio of 34.32, a PEG ratio of 3.05 and a beta of 1.08.

U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.52 by ($0.04). The company had revenue of $103.03 million for the quarter, compared to analysts’ expectations of $102.69 million. U.S. Physical Therapy had a return on equity of 13.37% and a net margin of 5.29%. research analysts expect that U.S. Physical Therapy, Inc. will post 2.07 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 8th. Investors of record on Friday, November 17th were issued a $0.20 dividend. The ex-dividend date was Thursday, November 16th. This represents a $0.80 annualized dividend and a yield of 1.10%. U.S. Physical Therapy’s dividend payout ratio (DPR) is currently 48.19%.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aberdeen Asset Management PLC UK grew its position in U.S. Physical Therapy by 13.4% in the 2nd quarter. Aberdeen Asset Management PLC UK now owns 705,007 shares of the company’s stock valued at $42,582,000 after acquiring an additional 83,253 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of U.S. Physical Therapy by 10.4% during the second quarter. Renaissance Technologies LLC now owns 668,074 shares of the company’s stock worth $40,352,000 after buying an additional 63,074 shares in the last quarter. Vanguard Group Inc. grew its position in shares of U.S. Physical Therapy by 2.2% during the second quarter. Vanguard Group Inc. now owns 655,524 shares of the company’s stock worth $39,594,000 after buying an additional 13,991 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of U.S. Physical Therapy by 1.5% during the third quarter. Dimensional Fund Advisors LP now owns 493,972 shares of the company’s stock worth $30,355,000 after buying an additional 7,197 shares in the last quarter. Finally, State Street Corp grew its position in shares of U.S. Physical Therapy by 3.8% during the second quarter. State Street Corp now owns 319,307 shares of the company’s stock worth $19,286,000 after buying an additional 11,645 shares in the last quarter. 99.75% of the stock is owned by institutional investors.

A number of research analysts have recently commented on USPH shares. Cantor Fitzgerald restated a “buy” rating and issued a $74.00 price target on shares of U.S. Physical Therapy in a report on Thursday, November 2nd. Zacks Investment Research upgraded shares of U.S. Physical Therapy from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a report on Tuesday, August 29th. Sidoti upgraded shares of U.S. Physical Therapy from a “neutral” rating to a “buy” rating and increased their target price for the stock from $62.00 to $74.00 in a report on Friday, September 8th. BidaskClub raised shares of U.S. Physical Therapy from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. Finally, Barrington Research downgraded shares of U.S. Physical Therapy from an “outperform” rating to a “market perform” rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $69.00.

TRADEMARK VIOLATION NOTICE: “U.S. Physical Therapy, Inc. (USPH) Director Clayton Trier Sells 4,250 Shares” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/u-s-physical-therapy-inc-usph-director-clayton-trier-sells-4250-shares/1761273.html.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.

Insider Buying and Selling by Quarter for U.S. Physical Therapy (NYSE:USPH)

Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with Analyst Ratings Network's FREE daily email newsletter.